Cargando…
Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia
OBJECTIVE: The protein encoded by mitogen-inducible gene 6 (MIG6) plays an essential role in the regulation of cholesterol homeostasis and bile acid synthesis in mice. However, the physiological functions of MIG6 remain poorly understood in humans. Therefore, we aimed to evaluate the relationship be...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943322/ https://www.ncbi.nlm.nih.gov/pubmed/35301888 http://dx.doi.org/10.1177/03000605221085079 |
_version_ | 1784673492941144064 |
---|---|
author | Lee, Jun Choul Kim, Ji Min Joung, Kyong Hye Kang, Seon Mee Kim, Hyun Jin Ku, Bon Jeong |
author_facet | Lee, Jun Choul Kim, Ji Min Joung, Kyong Hye Kang, Seon Mee Kim, Hyun Jin Ku, Bon Jeong |
author_sort | Lee, Jun Choul |
collection | PubMed |
description | OBJECTIVE: The protein encoded by mitogen-inducible gene 6 (MIG6) plays an essential role in the regulation of cholesterol homeostasis and bile acid synthesis in mice. However, the physiological functions of MIG6 remain poorly understood in humans. Therefore, we aimed to evaluate the relationship between the serum MIG6 concentration and low-density lipoprotein (LDL)-cholesterol in patients undergoing cholesterol-lowering treatment. METHODS: We performed a non-randomized, prospective controlled trial. In total, 63 patients with type 2 diabetes and hypercholesterolemia were treated using either rosuvastatin monotherapy or rosuvastatin/ezetimibe combination therapy for 12 weeks. We then compared their serum lipid and MIG6 concentrations before and after treatment. RESULTS: The serum LDL-cholesterol concentration of the participants significantly decreased and the concentration of MIG6 significantly increased during treatment. In addition, higher pre-treatment serum concentrations of MIG6 were associated with larger reductions in LDL-cholesterol, regardless of the therapeutic agent used. CONCLUSIONS: Serum MIG6 concentration significantly increases alongside the reduction in LDL-cholesterol achieved using cholesterol-lowering therapies in patients with diabetes and hypercholesterolemia. This is the first study to provide evidence that MIG6 may be involved in human cholesterol metabolism. CRIS registration number: KCT0003477. https://cris.nih.go.kr. |
format | Online Article Text |
id | pubmed-8943322 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | SAGE Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-89433222022-03-25 Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia Lee, Jun Choul Kim, Ji Min Joung, Kyong Hye Kang, Seon Mee Kim, Hyun Jin Ku, Bon Jeong J Int Med Res Prospective Clinical Research Report OBJECTIVE: The protein encoded by mitogen-inducible gene 6 (MIG6) plays an essential role in the regulation of cholesterol homeostasis and bile acid synthesis in mice. However, the physiological functions of MIG6 remain poorly understood in humans. Therefore, we aimed to evaluate the relationship between the serum MIG6 concentration and low-density lipoprotein (LDL)-cholesterol in patients undergoing cholesterol-lowering treatment. METHODS: We performed a non-randomized, prospective controlled trial. In total, 63 patients with type 2 diabetes and hypercholesterolemia were treated using either rosuvastatin monotherapy or rosuvastatin/ezetimibe combination therapy for 12 weeks. We then compared their serum lipid and MIG6 concentrations before and after treatment. RESULTS: The serum LDL-cholesterol concentration of the participants significantly decreased and the concentration of MIG6 significantly increased during treatment. In addition, higher pre-treatment serum concentrations of MIG6 were associated with larger reductions in LDL-cholesterol, regardless of the therapeutic agent used. CONCLUSIONS: Serum MIG6 concentration significantly increases alongside the reduction in LDL-cholesterol achieved using cholesterol-lowering therapies in patients with diabetes and hypercholesterolemia. This is the first study to provide evidence that MIG6 may be involved in human cholesterol metabolism. CRIS registration number: KCT0003477. https://cris.nih.go.kr. SAGE Publications 2022-03-18 /pmc/articles/PMC8943322/ /pubmed/35301888 http://dx.doi.org/10.1177/03000605221085079 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (https://creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage). |
spellingShingle | Prospective Clinical Research Report Lee, Jun Choul Kim, Ji Min Joung, Kyong Hye Kang, Seon Mee Kim, Hyun Jin Ku, Bon Jeong Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia |
title | Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia |
title_full | Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia |
title_fullStr | Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia |
title_full_unstemmed | Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia |
title_short | Serum MIG6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia |
title_sort | serum mig6 concentration is increased by cholesterol-lowering treatment in patients with type 2 diabetes mellitus and hypercholesterolemia |
topic | Prospective Clinical Research Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8943322/ https://www.ncbi.nlm.nih.gov/pubmed/35301888 http://dx.doi.org/10.1177/03000605221085079 |
work_keys_str_mv | AT leejunchoul serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia AT kimjimin serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia AT joungkyonghye serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia AT kangseonmee serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia AT kimhyunjin serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia AT kubonjeong serummig6concentrationisincreasedbycholesterolloweringtreatmentinpatientswithtype2diabetesmellitusandhypercholesterolemia |